Q-omics provides the consensus-scored SLC66A2 profile across patient tissues and cancer cell-line models. SLC66A2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC66A2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SLC66A2 RNA expression shows 17,719 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where SLC66A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC66A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC66A2 survival associations across molecular data types. SLC66A2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC66A2 RNA expression–survival associations across cancer types. High SLC66A2 expression shows unfavorable associations in ACC, MESO, LAML and BLCA, but favorable associations in UVM and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC66A2 RNA expression.
This table summarizes SLC66A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC66A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC66A2 shows lower tumor expression in THCA, COAD, LUAD, KICH and KIRP and higher tumor expression in KIRC. The THCA box plot shows higher SLC66A2 RNA expression in normal versus tumor tissue (log2 FC = −1.411, t-test p < 0.001).
This table shows molecular features associated with SLC66A2 in patient tissues and cancer cell lines. In patient samples, SLC66A2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC66A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
